Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a particular interest in mental health, gender-affirming care, and LGBTQ+ patient ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Real change will require a concerted effort from all of us — researchers, clinicians, regulators, policymakers, and investors — working in alignment to change the system where women’s health ...

Decades-old clinical resource UpToDate has launched Expert AI, a chatbot-like feature that offers quick answers to medical questions.

President Trump said there is “virtually no autism” among the Amish. A researcher who studies the health of the Amish says it’s complicated.

Shutting pregnant women out of clinical trials to protect them and their babies has had the opposite effect, experts say.

A new report finds there are fewer antibacterial medicines in clinical pipelines than just two years ago and relatively few qualify as innovative.

Patient groups urge U.K.’s antitrust regulator to investigate drugmakers for “suspected” and “coordinated” efforts to drive up the prices of medicines.

Researchers have found that ALS patients have autoimmune responses, a finding with the potential to reshape how scientists think of the devastating and complex neurologic disorder.

President Trump announced that Pfizer agreed to offer lower prices on its drugs to the Medicaid program and directly to patients ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. The government is shut down, but the First Opinion Podcast is back. Take a listen.